Innoviva, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+2.93%
vs ±5.8% implied · ×0.51
shaded = implied · ▲▼ = realized
Innoviva has 10 disclosed suppliers and 2 disclosed customers in SEC filings.
SentenceZEVTERA ® (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia , including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia, licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) ("Basilea") for U.S. commercialization and commercially launched in the third quarter of 2025;
INVA 10-Kaccession 0001193125-26-071776
SentenceWe exclusively license ZEVTERA ® (pre-packaging and labeling) from Basilea for the U.S. marketing rights.
INVA 10-Kaccession 0001193125-26-071776
SentenceWe also entered into a Commercial Supply Agreement with Corden Pharma CHENÔVE SAS ("Corden"), under which we engaged Corden to manufacture and supply certain products related to XACDURO ® and to perform certain services and studies.
INVA 10-Kaccession 0001193125-26-071776
SentenceXERAVA ® is marketed in the U.S. by our wholly owned subsidiary, Tetraphase Pharmaceuticals, Inc. ("Tetraphase"), and is marketed in Europe and Great Britain by PAION on behalf of Tetraphase and is marketed in mainland China, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines by Everest Medicines Limited ("Everest").
INVA 10-Kaccession 0001193125-26-071776
SentenceManufacturing of RELVAR ® /BREO ® ELLIPTA ® (FF/VI) and ANORO ® ELLIPTA ® (UMEC/VI) is performed by GSK.
INVA 10-Kaccession 0001193125-26-071776
SentenceGIAPREZA ® is marketed in the U.S. by La Jolla and is marketed in Europe and Great Britain by PAION Deutschland GmbH, a subsidiary of the Humanwell Healthcare Group, on behalf of La Jolla.
INVA 10-Kaccession 0001193125-26-071776
SentenceGIAPREZA ® is marketed in the U.S. by La Jolla and is marketed in Europe and Great Britain by PAION Deutschland GmbH, a subsidiary of the Humanwell Healthcare Group, on behalf of La Jolla.
INVA 10-Kaccession 0001193125-26-071776
SentenceOn December 11, 2020, we entered into the Partnership Agreement and invested $300 million of our cash reserves to be managed by Sarissa Capital as the investment manager to the Partnership.
INVA 10-Kaccession 0001193125-26-071776
SentenceXERAVA ® is marketed in the U.S. by our wholly owned subsidiary, Tetraphase Pharmaceuticals, Inc. ("Tetraphase"), and is marketed in Europe and Great Britain by PAION on behalf of Tetraphase and is marketed in mainland China, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines by Everest Medicines Limited ("Everest").
INVA 10-Kaccession 0001193125-26-071776
Innoviva, Inc.
21.21
Linked news
NewsExpected move
Inputsspot 21.22exp Nov 20ATM strike 20ATM straddle 4.00IV 98%